English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hepatitis C virus (HCV) infection is a major health problem. Egypt has the highest prevalence worldwide. Currently, combined pegylated interferon and ribavirin therapy is the standard treatment but the outcome is not satisfactory. The present study aimed To assess the possible association of serum IL-10 level, SOD activity in erythrocyte lysate and plasma MDA level and response to combined interferon α2a and ribavirin therapy in chronic HCV infection. In (Group I) who were not responded to pegylated interferon and rebavirin combination therapy we found the level of serum IL-10 and plasma MDA still high while antioxidant enzyme SOD activity reduced. While in (Group II) who responded to pegylated interferon and rebavirin combination therapy a circulating serum IL-10 and plasma MDA levels reduced but erythrocyte antioxidant enzyme SOD activity increased.

ASSESSMENT OF SERUM INTERLEUKIN-10 LEVEL IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN